Home/Pipeline/JNJ-1802

JNJ-1802

Treatment-Resistant Depression

Phase 2Active

Key Facts

Indication
Treatment-Resistant Depression
Phase
Phase 2
Status
Active
Company

About Johnson & Johnson

Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.

View full company profile

Other Treatment-Resistant Depression Drugs

DrugCompanyPhase
DSP-6745Sumitomo PharmaPhase 1
ML-104MapLight TherapeuticsPreclinical
PSG-301PharmaSGPPreclinical